Adaptive Bio Offers Next Gen Cancer Tests

Shutterstock photo

Founded by two brothers and spun out of the Fred Hutchinson Cancer Research Center, Adaptive Biotechnologies ( ADPT ) is a pioneer in immune-driven medicine with two commercial products and an extensive pipeline backed by collaborations with Microsoft and Genentech. Its core immunoSEQ research assay sequences T-cell and B-cell receptors to provide unique insights into a patient's immune system and has been used by over 2,000 academic researchers and 125 biopharmaceutical companies.

Here are three other things you need to know about Adaptive Biotechnologies:

See the IPO profile on IPO Pro

To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.

Start a Free Trial of IPO Pro

Coming Soon: Karuna Therapeutics ( KRTX )

The article Adaptive Bio Offers Next Gen Cancer Tests originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
Referenced Symbols: ADPT , KRTX

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?